A Phase II Study of Sintilimab Combined With Ipilimumab N01, Cetuximab and Dabrafenib in Patients With Microsatellite-Stable, BRAF V600E-Mutated Metastatic Colorectal Cancer

NCT07506109 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

49

Enrollment

OTHER

Sponsor class

Conditions

BRAF V600E
Colorectal Cancer
Sintilimab
MSS (Microsatellite Stable)
Cetuximab
Dabrafenib
Ipilimumab N01

Interventions

DRUG: Ipilimumab N01
DRUG: Sintilimab
DRUG: Cetuximab
DRUG: Dabrafenib

Sponsor

Tianjin Medical University Cancer Institute and Hospital